Forest Laboratories posted a net income of $286.11m for the third quarter 2010, or $1 per diluted share, compared to $186.66m, or $0.61 per diluted share, for the comparable period in 2009.
For the nine months ended 30 September 2010, Forest Laboratories has posted a net revenue of $2.16bn compared to $2.07bn for the year ago period.
For the nine months ended 30 September 2010, Forest Laboratories has posted a net income of $403.59m, or $1.37 per diluted share, compared to $449.56m, or $1.48 per diluted share, for the year ago period.
Forest Laboratories chairman and CEO Howard Solomon said that they were pleased with the financial results of the company in the just completed quarter and with the continued positive progress of their late-stage product development pipeline.
"During the quarter the FDA Anti-Infective Drugs Advisory Committee unanimously voted to recommend approval of Ceftaroline for the treatment of community acquired bacterial pneumonia (CABP) and for the treatment of acute bacterial skin and skin structure infections (ABSSSI)," Solomon said.
"During the quarter we were pleased to announce, along with our partner Ironwood Pharmaceuticals, positive top-line results from the first of two Phase III clinical trials assessing the efficacy and safety of the investigational drug, Linaclotide, as a potential treatment in patients with irritable bowel syndrome with constipation (IBS-C)."